Apogee Therapeutics Inc. (APGE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Apogee Therapeutics Inc. (APGE:NASDAQ), powered by AI.

Current Price
$88.33
Sector
Healthcare
What is the Apogee Therapeutics Inc. stock price forecast?

Apogee Therapeutics Inc. is currently trading at $88.33. View real-time AI analysis on Alpha Lenz.

What is Apogee Therapeutics Inc. insider trading activity?

View the latest insider trading data for Apogee Therapeutics Inc. on Alpha Lenz.

What is Apogee Therapeutics Inc.'s P/E ratio?

View Apogee Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Apogee Therapeutics Inc.

NASDAQ · APGE
$88.33-1.17(-1.31%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Apogee Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Apogee Therapeutics Inc.'s ROE is -31.6%. Explore profitability and growth together.

Ask for details

Company Overview

Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.

CEODr. Michael Thomas Henderson M.D.
SectorHealthcare
IndustryBiotechnology
Employees196

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
196Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-30.26%ROA
-31.57%ROE
-33.78%ROIC

Financial Health

$131.55MCash & Cash Equivalents
$-98.30MNet Debt
3.68%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Apogee Therapeutics Inc. (ticker: APGE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 196 employees.

The current price is $88.33 with a P/E ratio of -x and P/B of -x.

ROE is -31.57%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Apogee Therapeutics Inc. (APGE) Stock Forecast 2026 $88.33 — Price, Financials & Analyst Targets | Alpha Lenz